

# 6. AML Academy 2023

Study Alliance Leukemia – AML Cooperative Group – CELL



**SAL**  
Studienallianz  
Leukämie

**AMLCG**  
AML  
Cooperative Group



16th/17th November 2023

## PRELIMINARY AGENDA

### Thursday, 16th November 2023

#### AML Academy I

13:00–13:10	Welcome	
13:10–13:35	News from IDH mutations in AML	Sophie Steinhäuser, Kiel
13:35–14:00	Risk stratification in RUNX1 mutated disease	Tobias Herold, München
14:30–14:55	Update on CAR-T cell options in AML	Tim Sauer, Heidelberg
14:55–15:20	Molecular profiling of patients with cytogenetically normal acute myeloid leukemia and hyperleukocytosis	Karsten Spiekermann, München
15:20–15:45	NCDK7/12/13 inhibition and venetoclax in acute myeloid leukemia	Caroline Pabst, Heidenberg
16:15–16:40	Prognostic impact of Secondary Type Mutations in AML	Marius Bill, Dresden
16:40–17:05	Real-world data on Gemtuzumab Ozogamicin	Philippe Muller, Essen

#### AML Academy II

17:30–18:00	Targeted treatment in AML: My standards and my future bets	BeiGene	Ofir Wolach, Tel Aviv
18:00–18:30	Allo HCT: About the optimal	abbvie	Charles Craddock, Birmingham
18:30–19:15	How I treat newly diagnosed AML	Jazz Pharmaceuticals	Keith Pratz, Philadelphia
19:15–19:30	Closing remarks		
From 20:00	Networking dinner		

### Friday, 17th November 2023

#### SAL-AMLCG Steering Committee Meeting

08:00–10:00 Steering Committee Meeting

#### Joint Study Group Meeting of SAL, AMLCG

10:30–13:00 Updates on current, past and future projects and trials

Lunch Break

14:00–16:00 Updates on current, past and future projects and trials

Organizer



GWT-TUD GmbH  
Freibergerstr. 33  
01067 Dresden

Juliana Binder

Mobil: 0151 2333 7972  
juliana.binder@g-wt.de

## Location

Scandic Frankfurt Museumsufer  
Wilhelm-Leuschner-Straße 44  
60329 Frankfurt am Main

Und online via Zoom

Registration  
[www.aml-academy.de](http://www.aml-academy.de)

Main Sponsor



Sponsors



Sponsors



AbbVie Deutschland GmbH & Co. KG (20.000 €), Amgen GmbH (5.000 €), Astellas Pharma GmbH (10.000 €), BeiGene Ltd. (20.000 €), Bristol-Myers Squibb GmbH & Co. KGaA (10.000 €), Gilead (5.000 €), Janssen-Cilag GmbH (10.000 €), Jazz Pharmaceuticals (30.000 €), Neovii Biotech GmbH (5.000 €), Novartis Pharma GmbH (10.000 €), Pfizer (5.000 €), Servier Deutschland GmbH ( - €), Stemline Therapeutics Switzerland GmbH ( - €), Otsuka Pharma GmbH (10.000 €)